(DGX) Quest Diagnostics - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US74834L1008
Stock:
Total Rating 64
Risk 83
Buy Signal 0.29
| Risk 5d forecast | |
|---|---|
| Volatility | 21.8% |
| Relative Tail Risk | -13.9% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.84 |
| Alpha | 18.51 |
| Character TTM | |
|---|---|
| Beta | 0.153 |
| Beta Downside | 0.286 |
| Drawdowns 3y | |
|---|---|
| Max DD | 17.24% |
| CAGR/Max DD | 0.98 |
EPS (Earnings per Share)
Revenue
Description: DGX Quest Diagnostics
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 992.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 2.75 > 1.0 |
| NWC/Revenue: 0.91% < 20% (prev 2.26%; Δ -1.35% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.89b > Net Income 992.0m |
| Net Debt (6.50b) to EBITDA (2.03b): 3.20 < 3 |
| Current Ratio: 1.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (112.0m) vs 12m ago -0.88% < -2% |
| Gross Margin: 33.25% > 18% (prev 0.33%; Δ 3292 % > 0.5%) |
| Asset Turnover: 68.16% > 50% (prev 61.12%; Δ 7.05% > 0%) |
| Interest Coverage Ratio: 5.31 > 6 (EBITDA TTM 2.03b / Interest Expense TTM 274.0m) |
Altman Z'' 3.82
| A: 0.01 (Total Current Assets 2.38b - Total Current Liabilities 2.28b) / Total Assets 16.23b |
| B: 0.62 (Retained Earnings 9.99b / Total Assets 16.23b) |
| C: 0.09 (EBIT TTM 1.46b / Avg Total Assets 16.19b) |
| D: 1.12 (Book Value of Equity 9.97b / Total Liabilities 8.94b) |
| Altman-Z'' Score: 3.82 = AA |
Beneish M -3.04
| DSRI: 0.97 (Receivables 1.41b/1.30b, Revenue 11.04b/9.87b) |
| GMI: 0.99 (GM 33.25% / 32.86%) |
| AQI: 0.99 (AQ_t 0.68 / AQ_t-1 0.68) |
| SGI: 1.12 (Revenue 11.04b / 9.87b) |
| TATA: -0.06 (NI 992.0m - CFO 1.89b) / TA 16.23b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
What is the price of DGX shares?
As of March 03, 2026, the stock is trading at USD 210.25 with a total of 922,262 shares traded.
Over the past week, the price has changed by +1.36%, over one month by +13.65%, over three months by +15.70% and over the past year by +21.03%.
Over the past week, the price has changed by +1.36%, over one month by +13.65%, over three months by +15.70% and over the past year by +21.03%.
Is DGX a buy, sell or hold?
Quest Diagnostics has received a consensus analysts rating of 3.89.
Therefore, it is recommended to buy DGX.
- StrongBuy: 8
- Buy: 1
- Hold: 10
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DGX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 217.4 | 3.4% |
| Analysts Target Price | 217.4 | 3.4% |
DGX Fundamental Data Overview February 28, 2026
P/E Trailing = 24.1533
P/E Forward = 17.1233
P/S = 2.1281
P/B = 2.7996
P/EG = 1.4646
Revenue TTM = 11.04b USD
EBIT TTM = 1.46b USD
EBITDA TTM = 2.03b USD
Long Term Debt = 5.17b USD (from longTermDebt, last quarter)
Short Term Debt = 678.0m USD (from shortTermDebt, last quarter)
Debt = 6.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.50b USD (from netDebt column, last quarter)
Enterprise Value = 29.98b USD (23.48b + Debt 6.92b - CCE 420.0m)
Interest Coverage Ratio = 5.31 (Ebit TTM 1.46b / Interest Expense TTM 274.0m)
EV/FCF = 22.06x (Enterprise Value 29.98b / FCF TTM 1.36b)
FCF Yield = 4.53% (FCF TTM 1.36b / Enterprise Value 29.98b)
FCF Margin = 12.32% (FCF TTM 1.36b / Revenue TTM 11.04b)
Net Margin = 8.99% (Net Income TTM 992.0m / Revenue TTM 11.04b)
Gross Margin = 33.25% ((Revenue TTM 11.04b - Cost of Revenue TTM 7.37b) / Revenue TTM)
Gross Margin QoQ = 32.57% (prev 33.70%)
Tobins Q-Ratio = 1.85 (Enterprise Value 29.98b / Total Assets 16.23b)
Interest Expense / Debt = 0.92% (Interest Expense 64.0m / Debt 6.92b)
Taxrate = 24.04% (81.0m / 337.0m)
NOPAT = 1.11b (EBIT 1.46b * (1 - 24.04%))
Current Ratio = 1.04 (Total Current Assets 2.38b / Total Current Liabilities 2.28b)
Debt / Equity = 0.96 (Debt 6.92b / totalStockholderEquity, last quarter 7.17b)
Debt / EBITDA = 3.20 (Net Debt 6.50b / EBITDA 2.03b)
Debt / FCF = 4.78 (Net Debt 6.50b / FCF TTM 1.36b)
Total Stockholder Equity = 7.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.13% (Net Income 992.0m / Total Assets 16.23b)
RoE = 13.88% (Net Income TTM 992.0m / Total Stockholder Equity 7.15b)
RoCE = 11.82% (EBIT 1.46b / Capital Employed (Equity 7.15b + L.T.Debt 5.17b))
RoIC = 8.59% (NOPAT 1.11b / Invested Capital 12.87b)
WACC = 5.17% (E(23.48b)/V(30.40b) * Re(6.48%) + D(6.92b)/V(30.40b) * Rd(0.92%) * (1-Tc(0.24)))
Discount Rate = 6.48% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -0.44%
[DCF] Terminal Value 86.95% ; FCFF base≈1.18b ; Y1≈1.26b ; Y5≈1.51b
[DCF] Fair Price = 347.8 (EV 44.84b - Net Debt 6.50b = Equity 38.34b / Shares 110.2m; r=5.90% [WACC]; 5y FCF grow 7.41% → 2.90% )
EPS Correlation: 4.00 | EPS CAGR: -7.33% | SUE: 1.15 | # QB: 5
Revenue Correlation: 62.17 | Revenue CAGR: 1.94% | SUE: 1.63 | # QB: 3
EPS next Quarter (2026-06-30): EPS=2.86 | Chg7d=+0.024 | Chg30d=+0.115 | Revisions Net=+8 | Analysts=12
EPS current Year (2026-12-31): EPS=10.64 | Chg7d=+0.014 | Chg30d=+0.273 | Revisions Net=+11 | Growth EPS=+8.0% | Growth Revenue=+6.4%
EPS next Year (2027-12-31): EPS=11.48 | Chg7d=+0.063 | Chg30d=+0.220 | Revisions Net=+8 | Growth EPS=+7.9% | Growth Revenue=+3.7%
[Analyst] Revisions Ratio: +0.80 (9 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 7.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = +3.4% (Analyst 7.2% - Implied 3.8%)
P/E Forward = 17.1233
P/S = 2.1281
P/B = 2.7996
P/EG = 1.4646
Revenue TTM = 11.04b USD
EBIT TTM = 1.46b USD
EBITDA TTM = 2.03b USD
Long Term Debt = 5.17b USD (from longTermDebt, last quarter)
Short Term Debt = 678.0m USD (from shortTermDebt, last quarter)
Debt = 6.92b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.50b USD (from netDebt column, last quarter)
Enterprise Value = 29.98b USD (23.48b + Debt 6.92b - CCE 420.0m)
Interest Coverage Ratio = 5.31 (Ebit TTM 1.46b / Interest Expense TTM 274.0m)
EV/FCF = 22.06x (Enterprise Value 29.98b / FCF TTM 1.36b)
FCF Yield = 4.53% (FCF TTM 1.36b / Enterprise Value 29.98b)
FCF Margin = 12.32% (FCF TTM 1.36b / Revenue TTM 11.04b)
Net Margin = 8.99% (Net Income TTM 992.0m / Revenue TTM 11.04b)
Gross Margin = 33.25% ((Revenue TTM 11.04b - Cost of Revenue TTM 7.37b) / Revenue TTM)
Gross Margin QoQ = 32.57% (prev 33.70%)
Tobins Q-Ratio = 1.85 (Enterprise Value 29.98b / Total Assets 16.23b)
Interest Expense / Debt = 0.92% (Interest Expense 64.0m / Debt 6.92b)
Taxrate = 24.04% (81.0m / 337.0m)
NOPAT = 1.11b (EBIT 1.46b * (1 - 24.04%))
Current Ratio = 1.04 (Total Current Assets 2.38b / Total Current Liabilities 2.28b)
Debt / Equity = 0.96 (Debt 6.92b / totalStockholderEquity, last quarter 7.17b)
Debt / EBITDA = 3.20 (Net Debt 6.50b / EBITDA 2.03b)
Debt / FCF = 4.78 (Net Debt 6.50b / FCF TTM 1.36b)
Total Stockholder Equity = 7.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.13% (Net Income 992.0m / Total Assets 16.23b)
RoE = 13.88% (Net Income TTM 992.0m / Total Stockholder Equity 7.15b)
RoCE = 11.82% (EBIT 1.46b / Capital Employed (Equity 7.15b + L.T.Debt 5.17b))
RoIC = 8.59% (NOPAT 1.11b / Invested Capital 12.87b)
WACC = 5.17% (E(23.48b)/V(30.40b) * Re(6.48%) + D(6.92b)/V(30.40b) * Rd(0.92%) * (1-Tc(0.24)))
Discount Rate = 6.48% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -0.44%
[DCF] Terminal Value 86.95% ; FCFF base≈1.18b ; Y1≈1.26b ; Y5≈1.51b
[DCF] Fair Price = 347.8 (EV 44.84b - Net Debt 6.50b = Equity 38.34b / Shares 110.2m; r=5.90% [WACC]; 5y FCF grow 7.41% → 2.90% )
EPS Correlation: 4.00 | EPS CAGR: -7.33% | SUE: 1.15 | # QB: 5
Revenue Correlation: 62.17 | Revenue CAGR: 1.94% | SUE: 1.63 | # QB: 3
EPS next Quarter (2026-06-30): EPS=2.86 | Chg7d=+0.024 | Chg30d=+0.115 | Revisions Net=+8 | Analysts=12
EPS current Year (2026-12-31): EPS=10.64 | Chg7d=+0.014 | Chg30d=+0.273 | Revisions Net=+11 | Growth EPS=+8.0% | Growth Revenue=+6.4%
EPS next Year (2027-12-31): EPS=11.48 | Chg7d=+0.063 | Chg30d=+0.220 | Revisions Net=+8 | Growth EPS=+7.9% | Growth Revenue=+3.7%
[Analyst] Revisions Ratio: +0.80 (9 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 7.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = +3.4% (Analyst 7.2% - Implied 3.8%)